CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity Apr 22, 2024 12:00am EDT
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements Apr 01, 2024 4:26pm EDT
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors Jan 18, 2024 8:45am EST
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Jan 17, 2024 8:45am EST
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin Dec 18, 2023 8:35am EST
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure Dec 06, 2023 9:00am EST
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy Nov 22, 2023 9:05am EST